NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Eloxx Pharmaceuticals, Inc. ELOX
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.49
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 19-year series below
Revenue
Net income
Per share
USD -0.49
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-145.4%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 5.3M
total assets, end of FY2025
Total assetsUSD 5.3M
EquityUSD -11.9M
CashUSD 4.8M
Gross debtUSD 1.0M
Net debtUSD -3.8M
Current ratio0.31×
The company holds more cash than debt.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
·
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
−0.0
−0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.49
−0.84
−6.63
−16.65
−38.15
−0.86
−1.34
−1.45
−4.75
−2.60
1.67
−1.31
−2.53
−5.11
−7.81
−0.14
−0.67
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
−0
−0
−0
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
−615.2
−409.2
−148.9
−128.6
−146.8
−193.1
−1571.7
−99.6
−91.0
−59.0
−169.2
−127.1
−116.3
−196.1
−73.9
−46.8
Shares out B
0.00
0.00
0.00
0.00
0.00
0.04
0.04
0.04
0.03
0.00
0.02
0.02
0.01
0.00
0.09
0.08
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed